1887

Journal of Medical Microbiology logo

Volume 57, Issue 8

Angio-oedema as an unusual tolerable side effect of voriconazole therapy Free

Abstract

Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): AmB, amphotericin B , CRP, C-reactive protein , ESR, erythrocyte sedimentation rate , IA, invasive aspergillosis and VRC, voriconazole
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47299-0
2008-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/8/1028.html?itemId=/content/journal/jmm/10.1099/jmm.0.47299-0&mimeType=html&fmt=ahah

References

  1. Ally R., Schurmann D., Kreisel W., Carois G., Aguirrebengoa K., Dupont B., Hodges M., Troke P., Romero A. J. theEsophageal Candidiasis Study Group 2001; A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447–1454 [CrossRef]
     [Google Scholar]
  2. Bates D. W., Su L., Yu D. T., Chertow G. M., Seger D. L., Gomes D. R., Dasbach E. J., Platt R. 2001; Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693 [CrossRef]
     [Google Scholar]
  3. Denning D. W. 1998; Invasive aspergillosis. Clin Infect Dis 26:781–803 [CrossRef]
     [Google Scholar]
  4. Denning D. W., Griffiths C. E. 2001; Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26:648–653 [CrossRef]
     [Google Scholar]
  5. Denning D. W., Stevens D. A. 1990; Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12:1147–1201 [CrossRef]
     [Google Scholar]
  6. Denning D. W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H. 2002; Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571 [CrossRef]
     [Google Scholar]
  7. Ghannoum M. A., Kuhn D. M. 2002; Voriconazole – better chances for patients with invasive mycoses. Eur J Med Res 7:242–256
     [Google Scholar]
  8. Gunsilius E., Lass-Florl C., Mur E., Gabl C., Gastl G., Petzer A. L. 1999; Aspergillus osteoarthritis in acute lymphoblastic leukemia. Ann Hematol 78:529–530 [CrossRef]
     [Google Scholar]
  9. Herbrecht R., Denning D. W., Patterson T. F., Bennett J. E., Greene R. E., Oestmann J. W., Kern W. V., Marr K. A., Ribaud P. other authors 2002; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415 [CrossRef]
     [Google Scholar]
  10. Johnson L. B., Kauffman C. A. 2003; Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637 [CrossRef]
     [Google Scholar]
  11. Kirkpatrick W. R., McAtee R. K., Fothergill A. W., Rinaldi M. G., Patterson T. E. 2000; Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44:2865–2868 [CrossRef]
     [Google Scholar]
  12. Kohli R., Hadley S. 2005; Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 19:831–851 [CrossRef]
     [Google Scholar]
  13. Lazarus H. M., Blumer J. L., Yanovicjh S., Schlamm H., Romero A. 2002; Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42:395–402 [CrossRef]
     [Google Scholar]
  14. Mouas H., Lutsar I., Dupont B., Fain O., Herbrecht R., Lescure F. X., Lortholary O. theBone Invasive Aspergillosis Study Group 2005; Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40:1141–1147 [CrossRef]
     [Google Scholar]
  15. Murphy M., Bernard E. M., Ishimaru T., Armstrong D. 1997; Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41:696–698
     [Google Scholar]
  16. Perez-Gomez A., Prieto A., Torresano M., Díez E., Mulero J., Labiano I., Andreu J. L. 1998; Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 27:226–244 [CrossRef]
     [Google Scholar]
  17. Perfect J. R., Marr K. A., Walsh T. J., Greenberg R. N., DuPont B., de la Torre-Cisneros J., Just-Nübling G., Schlamm H. T., Lutsar I. other authors 2003; Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122–1131 [CrossRef]
     [Google Scholar]
  18. Pfaller M. A., Messer S. A., Hollis R. J., Jones R. N. 2002; Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillence Program, 2000. Antimicrob Agents Chemother 461032–1037 [CrossRef]
     [Google Scholar]
  19. Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M. J., Kleinermans D. 2002; Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553 [CrossRef]
     [Google Scholar]
  20. Stevens D. A., Kan V. L., Judson M. A., Morrison V. A., Dummer S., Denning D. W., Bennett J. E., Walsh T. J., Patterson T. F., Pankey G. A. 2000; Practice guidelines for diseases caused by Aspergillus . Clin Infect Dis 30:696–709 [CrossRef]
     [Google Scholar]
  21. Stratov I., Korman T. M., Johnson P. D. 2003; Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis 22:277–283
     [Google Scholar]
  22. Walsh T. J., Lutsar I., Driscoll T., Dupont B., Roden M., Ghahramani P., Hodges M., Groll A. H., Perfect J. R. 2002a; Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240–248 [CrossRef]
     [Google Scholar]
  23. Walsh T. J., Pappas P., Winston D. J., Lazarus H. M., Petersen F., Raffalli J., Yanovich S., Stiff P., Greenberg R. & other authors (2002b). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234 [CrossRef]
     [Google Scholar]
  24. Wingard J. R., Kubilis P., Lee L., Yee G., White M., Walshe L., Bowden R., Anaissie E., Hiemenz J., Lister J. 1999; Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407 [CrossRef]
     [Google Scholar]
  25. Winkelstein J. A., Marino M. C., Johnson R. B., Boyle J., Curnutte J. Jr, Gallin J. I., Malech H. L., Holland S. M., Ochs H. other authors 2000; Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47299-0
Loading

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error